Literature DB >> 27957206

ICD Implantation Practice Within Europe: How To Explain The Differences Beyond Economy?

Baccillieri Maria Stella1, Zorzi Alessandro2.   

Abstract

Implantable cardioverter defibrillators (ICD) offer the potential to prevent sudden cardiac death and demonstrated a survival benefit in high risk cardiac patients. ICD implantation rates vary significantly throughout the countries all over Europe although there are no major differences in cardiovascular morbidity among countries. ICD implantation rates in each European country may be influenced by economic factors, including the gross domestic product, its percentage devoted to public health, and organization of the health system. However, ICD implantation rates vary substantially also among countries with a high gross domestic product. Beyond economy, other important factors that may influence ICD implantation rates are lack of guidelines awareness and poor guidelines adherence especially when treating specific subgroup of patients (such as elderly and those with non ischemic cardiomyopathies).

Entities:  

Keywords:  Arrhythmic Death; Implantable Cardioverter Defibrillators; Primary Prevention; Secondary Preventionk; Sudden Cardiac Death

Year:  2015        PMID: 27957206      PMCID: PMC4955890          DOI: 10.4022/jafib.1262

Source DB:  PubMed          Journal:  J Atr Fibrillation        ISSN: 1941-6911


  23 in total

1.  Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest : the Cardiac Arrest Study Hamburg (CASH).

Authors:  K H Kuck; R Cappato; J Siebels; R Rüppel
Journal:  Circulation       Date:  2000-08-15       Impact factor: 29.690

2.  Physicians' knowledge and attitudes regarding implantable cardioverter-defibrillators.

Authors:  Saadia Sherazi; Wojciech Zareba; James P Daubert; Scott McNitt; Abrar H Shah; Mehmet K Aktas; Robert C Block
Journal:  Cardiol J       Date:  2010       Impact factor: 2.737

3.  Cost-effectiveness of defibrillator therapy or amiodarone in chronic stable heart failure: results from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT).

Authors:  Daniel B Mark; Charlotte L Nelson; Kevin J Anstrom; Sana M Al-Khatib; Anastasios A Tsiatis; Patricia A Cowper; Nancy E Clapp-Channing; Linda Davidson-Ray; Jeanne E Poole; George Johnson; Jill Anderson; Kerry L Lee; Gust H Bardy
Journal:  Circulation       Date:  2006-07-03       Impact factor: 29.690

4.  Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.

Authors:  Arthur J Moss; Wojciech Zareba; W Jackson Hall; Helmut Klein; David J Wilber; David S Cannom; James P Daubert; Steven L Higgins; Mary W Brown; Mark L Andrews
Journal:  N Engl J Med       Date:  2002-03-19       Impact factor: 91.245

5.  Cardiovascular disease in Europe 2014: epidemiological update.

Authors:  Melanie Nichols; Nick Townsend; Peter Scarborough; Mike Rayner
Journal:  Eur Heart J       Date:  2014-08-19       Impact factor: 29.983

6.  A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias.

Authors: 
Journal:  N Engl J Med       Date:  1997-11-27       Impact factor: 91.245

7.  Canadian implantable defibrillator study (CIDS) : a randomized trial of the implantable cardioverter defibrillator against amiodarone.

Authors:  S J Connolly; M Gent; R S Roberts; P Dorian; D Roy; R S Sheldon; L B Mitchell; M S Green; G J Klein; B O'Brien
Journal:  Circulation       Date:  2000-03-21       Impact factor: 29.690

8.  Statistics on the use of cardiac electronic devices and electrophysiological procedures in the European Society of Cardiology countries: 2014 report from the European Heart Rhythm Association.

Authors:  M J Pekka Raatikainen; David O Arnar; Katja Zeppenfeld; Jose Luis Merino; Francisco Levya; Gerhardt Hindriks; Karl-Heinz Kuck
Journal:  Europace       Date:  2015-01       Impact factor: 5.214

9.  Estimation of the requirement for implantable cardioverter defibrillators for the primary prevention of sudden cardiac death post-myocardial infarction based on UK national guidelines (2006).

Authors:  P A Scott; S Gorman; N P Andrews; P R Roberts; P R Kalra
Journal:  Europace       Date:  2008-03-03       Impact factor: 5.214

10.  Limitations of ejection fraction for prediction of sudden death risk in patients with coronary artery disease: lessons from the MUSTT study.

Authors:  Alfred E Buxton; Kerry L Lee; Gail E Hafley; Luis A Pires; John D Fisher; Michael R Gold; Mark E Josephson; Michael H Lehmann; Eric N Prystowsky
Journal:  J Am Coll Cardiol       Date:  2007-09-04       Impact factor: 24.094

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.